Share-based Payment Arrangement, Expense of Candel Therapeutics, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Candel Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Candel Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,163,000, a 1.8% decline year-over-year.
  • Candel Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,771,000, a 25% decline year-over-year.
  • Candel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,312,000, a 72% increase from 2023.
  • Candel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,091,000, a 34% increase from 2022.
  • Candel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,307,000, a 22% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Candel Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,771,000 $1,163,000 -$21,000 -1.8% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $3,792,000 $1,050,000 -$791,000 -43% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $4,583,000 $314,000 -$729,000 -70% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $5,312,000 $1,244,000 +$305,000 +32% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $5,007,000 $1,184,000 +$498,000 +73% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $4,509,000 $1,841,000 +$1,108,000 +151% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $3,401,000 $1,043,000 +$310,000 +42% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $3,091,000 $939,000 +$305,000 +48% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $2,786,000 $686,000 -$57,000 -7.7% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $2,843,000 $733,000 +$295,000 +67% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $2,548,000 $733,000 +$241,000 +49% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $2,307,000 $634,000 +$1,080,000 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $1,227,000 $743,000 -$1,166,000 -61% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $2,393,000 $438,000 -$631,000 -59% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $3,024,000 $492,000 +$61,000 +14% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $2,963,000 $446,000 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $1,909,000 +$1,826,000 +2200% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,069,000 +$766,000 +253% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $431,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $83,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $303,000 01 Apr 2020 30 Jun 2020 10-Q 08 Sep 2021 2021 Q2

Candel Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,312,000 +$2,221,000 +72% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $3,091,000 +$784,000 +34% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $2,307,000 -$656,000 -22% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $2,963,000 +$856,000 +41% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $2,107,000 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.